Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hedgepath gets exclusive rights to Mayne's itraconazole formulation for cancer

Executive Summary

Mayne Pharma International Pty. Ltd. (branded and generic drugs; division of Mayne Pharma Group Ltd.) has granted cancer drug developer HedgePath Pharmaceuticals Inc. (formerly Commonwealth Biotechnologies) exclusive US rights to develop and sell its proprietary preclinical formulation of itraconazole for multiple cancers, initially prostate, lung, and skin.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies